2017
DOI: 10.1016/j.jhep.2017.02.012
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
29
0
4

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 45 publications
(39 citation statements)
references
References 26 publications
6
29
0
4
Order By: Relevance
“…This reinforces the message to treat all HIV/HCV co‐infected patients for their hepatitis as for HCV mono‐infected patients, especially given that there are no more differences in the response rate to new DAAs between both populations, with a rate of SVR reaching 93%‐95% in clinical trials as in real‐life studies whatever the combinations of DAAs used . Moreover, eradication of HCV infection in patients with cirrhosis has been shown to reduce the risk of HCC, decompensation, and nonliver complications such as cardiovascular events and bacterial infections .…”
Section: Discussionsupporting
confidence: 53%
“…This reinforces the message to treat all HIV/HCV co‐infected patients for their hepatitis as for HCV mono‐infected patients, especially given that there are no more differences in the response rate to new DAAs between both populations, with a rate of SVR reaching 93%‐95% in clinical trials as in real‐life studies whatever the combinations of DAAs used . Moreover, eradication of HCV infection in patients with cirrhosis has been shown to reduce the risk of HCC, decompensation, and nonliver complications such as cardiovascular events and bacterial infections .…”
Section: Discussionsupporting
confidence: 53%
“…In a French HCV/HIV cohort, an overall SVR rate of 93% was reported with no difference among those with cirrhosis. (78) Similarly high real-world rates of SVR have been described elsewhere, making drug interactions the main clinical issue with HCV treatment.…”
Section: Management Of Hcv/hivmentioning
confidence: 64%
“…Several studies have shown that HCV clearance by DAA treatments improves IR in patients with mild liver fibrosis but not in patients with advanced liver fibrosis . Therefore, prospective studies should be conducted to assess the impact of early treatment of HCV infection, and of high rates of SVR with DAA treatments, on the occurrence of DM …”
Section: Discussionmentioning
confidence: 99%